Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer
Primary Purpose
Cancer
Status
Unknown status
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by

About this trial
This is an observational trial for Cancer focused on measuring breast cancer, platelets, metastatic cancer, malignancy
Eligibility Criteria
Inclusion Criteria:
- Patients with a diagnosis of malignancy
Exclusion Criteria:
- Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy
Sites / Locations
- University of Vermont/Fletcher Allen Health CareRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01148407
Brief Title
Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer
Official Title
Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer
Study Type
Observational
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Unknown status
Study Start Date
June 2010 (undefined)
Primary Completion Date
August 2012 (Anticipated)
Study Completion Date
August 2013 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University of Vermont
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
Keywords
breast cancer, platelets, metastatic cancer, malignancy
7. Study Design
Enrollment
30 (Anticipated)
Biospecimen Retention
Samples Without DNA
Biospecimen Description
plasma, serum and platelet activated blood samples
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with a diagnosis of malignancy
Exclusion Criteria:
Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy
Study Population Description
Patients with a malignancy diagnosis.
Sampling Method
Probability Sample
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chris E Holmes, MD, PhD
Phone
802-656-0302
Email
ceholmes@uvm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chris E Holmes, MD PhD
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Vermont/Fletcher Allen Health Care
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Kelly
Email
bkelly@uvm.edu
First Name & Middle Initial & Last Name & Degree
Chris E Holmes, MD PhD
12. IPD Sharing Statement
Learn more about this trial
Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer
We'll reach out to this number within 24 hrs